Health care and pharmaceutical industry leader John Klein has spent nearly nine years as the chairman of Cambridge Therapeutics in Alpine, NJ. Concurrent with his leadership role at Cambridge Therapeutics, John Klein leads the enterprise performance management (EPM) firm Bilogix as its chairman and CEO.
A unique feature of Cognizant’s EPM practice is the early warning system (EWS). An emerging tool in the field of EPM, Cognizant’s EWS is highlighted by an array of fully integrated predictive features. The system’s intuitive framework allows for key performance indicator (KPI) forecasting that immediately alerts business leaders to potential threats.
All metrics monitored through Cognizant’s EWS are displayed at both their real-time values and through various predictive models derived from analytical simulations and other statistical techniques. Furthermore, the system features interactive KPI dashboards and scorecards that make metrics easily accessible across a number of business units and leadership levels. The EWS can be optimized through Cognizant’s custom SIMPOSM assessment tool, which gauges overall customer readiness for EPM intervention.
Healthcare industry executive John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In his supervisory role at Cambridge Therapeutics, John Klein sets the strategic direction for the company and remains familiar with new political and community developments affecting healthcare.
A new initiative that promotes the addition of affordable housing in the neighborhoods around New Jersey hospitals has received more funding and support than previously expected.
The executive director of the New Jersey Housing and Mortgage Finance Agency (HMFA), Charles Richman, originally announced that the project would receive $12 million from the organization. However, hospitals are matching the capital awarded by the HMFA, thus boosting the total to a minimum of $48 million. On top of that, Richman believed the state would fund only three or four alliances with medical facilities. However, at least six hospital-housing partnerships will be established by 2020, and the HMFA is hopeful this amount will increase to eight.
The first venture backed by this initiative is being completed on a vacant lot in Paterson. Resulting from a partnership between the HMFA and St. Joseph’s University Medical Center, the project is a 70-unit development that will feature one- to three-bedroom apartments. These units will largely be reserved for low-income residents, many of whom can benefit from hospital services.
An accomplished pharmaceutical executive with more than 20 years of industry experience, John Klein serves as the chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to his responsibilities at Cambridge Therapeutics, John Klein actively follows health-related news affecting NJ.
Home healthcare agencies in NJ recently warned of a future shortage of private duty nurses (PDNs) in the state. Pointing to lower-than-desired Medicaid reimbursement rates, agency representative said that they are experiencing difficulties recruiting qualified nurses for home-based services. PDNs provide around-the-clock care for medically complex patients in their homes, sometimes tending to individuals who are cognitively impaired or born with congenital defects.
Licensed as either a registered nurse or a licensed practical nurse, PDNs are paid through Medicaid reimbursements, making it hard for them to earn as much as their hospital-based counterparts. More than a decade has passed since the last Medicaid-reimbursement increase.
According to an internal study by BAYADA Home Health Care, the home healthcare industry attracts only 17 percent of registered nurses and 40 percent of licensed practical nurses, leaving many patients without the nursing care they need.
The recipient of a master of business administration from Roosevelt University, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to guiding Cambridge Therapeutics’ strategic direction, John Klein closely follows health-related developments in NJ.
Recently, the state’s largest hospital, Bergen New Bridge Medical Center, and NJ’s biggest insurance company, Horizon Blue Cross Blue Shield (Horizon BCBS), announced the formation of a new partnership. In July 2019, NJ Governor Phil Murphy joined representatives from Bergen New Bridge, Horizon BCBS, and Bergen County to celebrate the alliance, which is expected to increase access to multiple healthcare services for local residents.
The new agreement will enable Bergen New Bridge to accept insurance for approximately 230,000 Horizon BCBS members in Bergen County and others whose plans were previously denied. Governor Murphy praised the cooperation, stating that expanding access to the addiction-rehabilitation program and other means of aid at the hospital will help fill treatment gaps in the state.
An alumnus of Roosevelt University with a BS and an MBA, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. Aside from providing experienced leadership to Cambridge Therapeutics, John Klein closely follows developments in NJ health policy.
To fight the opioid addiction crisis, New Jersey recently introduced a program that will train hundreds of additional health care professionals in medication-assisted treatment (MAT). Considered the best treatment approach for opioid addiction, MAT combines outpatient counseling and treatment services with medication, usually buprenorphine, which works to block cravings and the high associated with heroin and other opioid use.
In partnership with medical schools in Camden and Newark, the NJ Department of Human Services will help physicians, advanced practice nurses, and physician assistants obtain the required training and federal certification to administer MAT to patients, allocating $2 million in funding. The New Jersey State Nurses Association and the Medical Society of New Jersey praised the state’s initiative to combat the opioid epidemic and increase capacity for addiction treatment in NJ.
With nearly 30 years of experience in the healthcare and pharmaceutical industries, John Klein currently serves as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. To inform the strategic decisions he makes as chairman of Cambridge Therapeutics, John Klein closely follows health policy developments in New Jersey.
The New Jersey State Assembly recently drafted a bipartisan bill to improve palliative care in the state. In addition to creating an 11-member advisory council on palliative care, the proposal would require hospitals, nursing homes, and other long-term care facilities to provide educational resources to patients and families about end-of-life care options.
Backed by about three dozen sponsors, the bill aims to increase public awareness about the full range of palliative care options and create a proactive system where care providers engage in educational outreach work. Providing different options for palliative care gives patients more control and may help ease some of the pain and anxiety associated with a terminal diagnosis, said Samantha DeAlmeida, a representative of the American Cancer Society, an organization that’s backing the New Jersey bill.